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1Chapter
Pharmacoeconomical Impacts of 
Crohn’s Disease
Stjepan Rudan, Rudika Gmajnić and Sanda Pribić
Abstract
Provide an overview of Crohn’s disease and its cost assessment options, establish 
the need for implementing Croatian national Crohn’s Disease Registry to precisely 
quantify the costs and the outcomes, and establish model to evaluate values of treat-
ment options for Crohn’s disease.
Keywords: Crohn’s disease,farmacoeconomical impact
1. Introduction
Crohn’s disease is a chronic, progressive inflammatory bowel disease (IBD). 
Although mortality is rare, Crohn’s disease significantly impacts quality of life as it 
causes significant disabilities related to the debilitating symptoms and complica-
tions of the disease and its treatment. As such, IBD exerts physical, social, sexual, 
emotional, educational, and job-related limitations. Therefore Crohn’s disease 
produces a huge burden on patients, families, and societies.
While it is clear that new biological therapies have raised the bar for what is an 
acceptable symptomatic response in Crohn’s disease, the key pharmacoeconomical 
and humanical questions are whether TNF antagonists can reduce hospitalization 
and surgery rates or can, if applied in earlier stages, modify the course of the disease 
by means of fistula healing, mucosal healing, and overall improvement in QOL [1].
Novel therapies and alternative treatment algorithms require that healthcare 
providers evaluate the value of these treatments. Pharmacoeconomic analyses aim 
to assess whether new technologies are superior to existing treatments by relating 
costs to outcomes.
In the absence of the national registry, in Croatia, we do not have national data 
on Crohn’s disease; therefore in this paper, we can only apply epidemiological 
models to project Crohn’s disease costs and pharmacoeconomically evaluate treat-
ment options.
2. How to evaluate CD therapies: clinical indexes and endpoints
Traditional primary endpoints in clinical trials (i.e., Crohn’s Disease Activity 
Index (CDAI)) quantify physical symptoms, without incorporating overall “illness 
experience.”
Therefore, QOL measures are commonly used as secondary endpoints in 
clinical trials, and several QOL tools are available. Since the first being created in 
1985, the development of IBD questionnaires has substantially advanced studies 
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of HRQOL. In addition to the common physical complaints associated with CD, 
IBDQ also measures social, functional, and psychological factors, and it has strong 
correlation to CD (Shah 1). A total of 32 items comprise the questionnaire, being 
grouped into 4 major domains (bowel function, social function, emotional  
functional, and systemic function). Total score ranges from 32 to 224 points, higher 
score indicating better QOL (Shah 2). Several validation studies of IBDQ were 
performed in different populations confirming its validity (Shah 3). A score above 
170 is considered desirable [2–4].
To better address patient concerns in regard to the effects of the disease and 
their health status, rating form of IBD patient concerns was developed [5].
However, review study assessing several HRQOL tools led to the conclusion that 
IBDQ was simple, reliable, and accurate in disease activity assessment and therefore 
more favorable than other instruments [6].
3. Medical treatments: outcomes
Corticosteroids have long been used in the management of Crohn’s disease. 
They demonstrate rapid onset of action and efficacy while having significant side 
effect profile and lack of maintenance benefit [7]. The need for corticosteroids’ use 
is a significant indicator of future disabling disease and complications, including 
mortality [8, 9]. One analysis has shown that Crohn’s disease patients using cortico-
steroids had 38% risk for surgery in 1 year [10].
While it is clear that new biological therapies have raised the bar for what is an 
acceptable symptomatic response in Crohn’s disease, the key pharmacoeconomical 
and humanical questions are whether TNF antagonists can reduce hospitalization 
and surgery rates or can, if applied in earlier stages, modify the course of the disease 
by means of fistula healing, mucosal healing, and overall improvement in QOL.
ACCENT I trial has clearly demonstrated efficacy of infliximab maintenance 
treatment in patients with fistulizing Crohn’s disease [11]. Further subgroup analy-
sis has shown that in patients randomized to maintenance infliximab treatment 
following successfully induction therapy, the mean number of hospital days per 
100 patients treated was significantly reduced in the group of patients assigned to 
infliximab compared with those who received placebo [12]. Significant reductions 
in the rates of surgery and procedures were also demonstrated [12].
CHARM trial [13] confirmed adalimumab efficacy and safety in moderate to 
severe Crohn’s disease. Based on CHARM data, the effect of ongoing adalimumab 
treatment on the risk for hospitalization was evaluated [14]. It showed a significant 
difference between placebo and adalimumab group, demonstrating relative risk 
reduction of 57% and absolute risk reduction 8%, showing the difference between 
the treatment groups early in the course of the therapy. Multivariable analysis 
confirmed that assignment to adalimumab therapy was inversely correlated with 
the risk of hospitalization and surgery.
These studies confirmed that TNF antagonists can reduce the risk of hospitaliza-
tion and surgery in Crohn’s disease. Together with Lemann trial on infliximab [15], 
both trials confirmed that anti-TNF agents are effective steroid-sparing agents.
In the provocative trial inverting the treatment pyramid [16], newly diagnosed 
patients with symptomatic disease were randomized either to infliximab + azathio-
prine combination (top-down group) or to steroids initially (step-up group), which 
were increased if patients flared during taper, or azathioprine and a second course 
of steroids if patients flared after the initial steroid course was completed. If symp-
toms recurred, or the response was inadequate, infliximab was given. Remission 
of steroids without surgery was achieved in 60% of patients in top-down group 
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vs. 36% of patients in step-up group at 26 weeks and 62% vs. 42% of the patients, 
respectively, at 56 weeks.
As approximately one third of the patients with Crohn’s disease will develop 
fistulas at some point in the disease course [17], it is important to underline that 
both infliximab [18] and adalimumab [13] were proven effective for the partial or 
complete healing of fistulas in patients with Crohn’s disease, maintaining the effect 
among responders in majority of patients at 1 year.
Mucosal healing as a potential disease-modifying point was reported supe-
rior in patients receiving infliximab in an endoscopic sub study of the ACCENT 
I trial [19]. This is even more important knowing that mucosal healing findings 
have not correlated well with clinical remission by CDAI: 56% of patients in 
remission by CDAI did not have mucosal healing. The reasons for this remain 
unclear.
In a sub study of step-up was top-down trial [20], 44 patients were endo-
scopically evaluated at year 2 from initiation of the treatment, and results were 
compared with endoscopy findings at the diagnosis. For the comparison, five 
ileal and colonic segment lesions were scored for each patient. Complete ulcer 
disappearance was observed in 71% of patients who received top-down vs. 30% of 
patients who received step-up treatment. Mucosal healing was more pronounced 
in top-down group, with ulcer reductions observed in 88% of patients in top-
down vs. 47% of patients in step-up group. The results indicate that infliximab 
is effective for the induction of mucosal healing. Effects of adalimumab have not 
been reported.
Finally, both infliximab and adalimumab were associated with improvements in 
QOL scores:
ACCENT I studied HRQOL [21], suggesting substantial impairment HRQOL at 
baseline scores and substantial improvements throughout the infliximab mainte-
nance therapy.
CLASSIC II trial [22] demonstrated that patients on maintenance adalimumab 
therapy achieving remission have demonstrated improvements in IBDQ that were 
maintained throughout 1 year.
It can be concluded that both infliximab and adalimumab are significantly more 
effective in improving both CDAI and HRQOL than other treatment options. Also, it is 
suggested that reverting the treatment algorithm and introducing infliximab earlier on 
(top-down approach) may result in better mucosal healing and therefore modify the 
course of the disease.
4. Costs of the disease
Crohn’s disease patients are typically diagnosed at their young age, and the treat-
ment is generally lifelong.
Patients require chronic drug therapy due to the recurrent episodes of abdomi-
nal pain, diarrhea, and bleeding. Conventional therapies (glucocorticoids and 
immunosuppressives) are effective but associated with considerable side effects. 
Biological therapies have been introduced into routine clinical use, improving the 
disease outcomes over the past decade [11–14]; however, the costs related to novel 
options are substantially higher.
Hospitalization and surgeries are often needed to manage complications such 
as abscesses, perforations, and obstructions. Bowel resections are associated with 
considerable morbidity and, infrequently, death.
It is clear that both symptoms and the treatment of Crohn’s disease reduce 
patients’ health-related quality of life (HRQOL).
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Cost of illness studies has showed that hospitalization and surgery are major 
factors of the total societal costs of Crohn’s disease [23–25].
But above these obvious disease management costs, work loss and impaired 
HRQOL increase the humanistic and economic burden in Crohn’s disease.
4.1 Direct costs: disease management costs—course and prognosis related
Direct costs are easily identifiable and quantifiable. The costs of Crohn’s disease 
include outpatient care costs (medications, tests, procedures) and inpatient care 
costs (hospitalization).
In a prospective study [26], 33% of patients with chronic or intermittently active 
disease required hospitalization and surgery after developing complications in the 
first year following diagnosis, and 13% required hospitalization and surgery in the 
second year and 3% in each following year.
The same study showed that 20% of CD patients were unable to work at full 
capacity 20 years after the time of diagnosis. Another long-term follow-up study 
showed that approximately 74% of all patients with CD will eventually be hospital-
ized and ultimately require surgical intervention for their disease [27].
4.2  Indirect costs: total economic loss experienced by patients, caregivers,  
and society/HRQOL-related costs
Indirect costs are more subjective than direct costs. In Crohn’s disease, sources of 
indirect costs include absence from work, premature retirement, and the social and 
psychological effects of chronic disease on patients and their families.
As a consequence of the Crohn’s disease course and prognosis, HRQOL is 
diminished and directly correlates with a higher likelihood of unemployment [28]. 
In a case-controlled study [29], adult patients with CD were reported to have more 
long-term unemployment than controls. Furthermore, in the same study, up to 30% 
of CD patients were reported to concealed their illness from their employers.
As determined in ACCENT I [30], there were high unemployment rates of 27% 
in males and 44% in females among Crohn’s disease patients. However, only 25% of 
patients received disability benefits. This further strengthens economic burden of 
Crohn’s disease to society.
5. How to evaluate CD therapies: costs vs. outcomes
As societal resources for healthcare are limited, sound methodology for resource 
allocation is needed. Pharmacoeconomic analyses address this issue, considering 
costs (currency) and the consequences of the therapy. In 2007 Feagan [31] posted 
an effective overview of the methodology, commonly classified into four categories: 
cost-minimization, cost-effectiveness, cost–benefit, and cost-utility analyses. The dif-
ferences between methodologies are based on the outcome to which costs are related.
When two competing interventions have equivalent clinical outcomes, it is logi-
cal to use Cost-minimization analysis. Being the most simple analysis, it favors less 
costly treatment when no clinical difference has been demonstrated.
In more often, real-life cases, when we are faced with new therapies that are both 
more effective and more expensive, we have to relate different costs and different 
outcomes. Therefore other more sophisticated methodologies are needed [32].
Cost-effectiveness analysis relates costs to clinically meaningful differences in 
outcomes: per beneficial outcome attained, the incremental cost of a novel therapy 
is then expressed in terms of currency expended. It can be used in indications where 
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robust endpoints exist (i.e., myocardial infarction prevention) and the incremental 
costs are easily understood by patients and providers [32].
Cost-benefit analysis translates differences in outcomes into monetary terms, 
as they are for the costs. This brings two inputs into the same units, and the com-
parison between the treatments is easily interpreted. Logically, the strategy that 
maximizes net value for the society (net currency gained) is preferred. Relevance 
of this technique in terms of healthcare applicability is challenged: it requires value 
judgments, which are usually inappropriate [33].
Cost-utility analysis expresses currency expended per incremental improvement in 
HRQOL achieved. It evaluates well chronic diseases with serious impact on HRQOL, but 
without causing excess mortality or frequent complications. The HRQOL measure used 
is utility. This is a generic metric placing a value on HRQOL, ranging from 1 (perfect 
health) to 0 (death). Quality-adjusted life years (QALYs) are then derived by multiply-
ing the time in a health state by the appropriate utility score. Logically, differences 
between treatments are expressed as the incremental costs per QALY gained [34].
Cost of illness studies identify where efficacies can be realized. These studies are 
descriptive evaluations that (1) assess the total economic burden of the disease; (2) 
define the relative proportions of total costs allocated to diagnostic tests, healthcare 
professionals, institutions, and drugs; and (3) generate hypotheses regarding the 
economic consequences of treatment alternatives.
Only a few such studies have been reported for Crohn’s disease.
A cost model for IBD was created in the early 1990s using data from a California 
health maintenance organization [23]. Reducing the charges obtained from a 
teaching hospital in San Francisco by 35%, the mean annual medical cost of Crohn’s 
disease was estimated to be 6561$ per person. It was demonstrated that approxi-
mately 20% of patients generate 80% of healthcare costs. Surgery and hospitaliza-
tion were associated with 79.9% of the average costs of medical services. Drug 
therapy was responsible for 10.2% of the total costs. By extrapolating these data 
to the US population, using published prevalence estimates and 1990 census data, 
the total direct cost of Crohn’s disease was estimated to be 1–1.2 billion annually, 
compared to 0.4–0.6 billion for ulcerative colitis. The indirect costs of the disease 
were estimated based exclusively on lost labor productivity and calculated 0.4–0.8 
billion annually. Therefore, the total (direct + indirect) economic burden for IBD 
(Crohn and UC) was estimated to be 1.8–2.6 bio $ yearly [23].
Feagan’s study [24] evaluated reimbursement charges from patients enrolled 
in a health benefit claims program serving 50 largest US employers. Eligible 
patients were enrolled in their health plan for a minimum of 3 years and had at 
least 1 CD-related claim over a 1-year interval (1994/1995). The study retrospec-
tively classified patients into three mutually exclusive status: mild (patients in 
remission or those requiring less than 6 months of active treatment during the 
observation period), moderate (patients who required chronic treatment for more 
than 6 months with prednisone or antimetabolites), and severe disease (patients 
requiring admission to hospital for treatment). A total of 607 patients generated 
average annual charges of 12.417$ per patient: 6.277$ being the average for the 
mild, 10.033$ for the moderate, and 37.135$ for the severe form of the disease.
These studies suggest that treatments that reduce the need for hospitalization or 
surgery may result in important cost savings.
As quoted earlier on, two subgroups of large randomized clinical trials have 
strongly indicated that the use of TNF antagonists reduces the rate of hospitaliza-
tion and surgery in Crohn’s disease [12, 14].
It is important to evaluate in economic models whether the potential offsets that 
result from reduced rates of hospitalization and surgery justify the high price of 
biological.
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Lindsay et al. [35] used Markov models to simulate the disease progression and 
track associated costs and outcomes as QALYs over 5 years of treatment in hypo-
thetical cohort of patients with active luminal or fistulizing CD, during treatment 
with infliximab (5 mg/kg). Transitions were estimated from published clinical 
trials of infliximab. Standard care, comprising immunomodulators, and seven 
corticosteroids were used as a comparator. An average weight of 60 kg was used to 
estimate the dose of infliximab. Authors discounted the costs and outcomes 3.5% 
over 5 years. The primary effectiveness measurement was quality-adjusted life 
years estimated using EQ-5D. One-way and probabilistic sensitivity analyses were 
used by varying infliximab efficacy estimates, costs, and utilities. The incremental 
costs per QALY gained were 26.128P in luminal and 29.752 in fistulizing CD at 
5 years. Results were robust, remaining in the range of 23.752–38.848 for luminal 
and 27.047–44.206 for fistulizing CD. Not surprisingly, the most important factor 
affecting cost-effectiveness was patients’ body weight. The authors concluded that 
8-week scheduled maintenance treatment with infliximab is a cost-effective treat-
ment for adult patients suffering from active luminal or fistulizing CD.
6. Where we are in Croatia and how we should move forward
In Croatia there is no national registry of Crohn’s disease. Therefore, we are 
lacking precise epidemiological data that are essential for high-quality cost-utility/
HRQOL assessments.
Consequently, we do not have exact data on the total incidence and prevalence 
of the disease. We cannot precisely conclude how many of Croatian patients are 
suffering from the mild, moderate, or severe form of the disease. We also cannot 
confirm precise age or weight distribution of the patients. We also do not know 
the educational distribution or the rate of unemployment among Crohn’s disease 
patients.
As it concerns outpatient care costs, while we can find IMS data or HZZO data 
on total cost of biological therapies, we do not have the access to cost split per 
indication. Also we are not aware on how much resources are allocated to other 
outpatient care elements.
Furthermore, we cannot define essential resource allocation inputs for Crohn’s 
disease. There is no available source to confirm the exact number of hospital days/
related costs due to Crohn’s disease or to provide exact number of surgery proce-
dures/related costs undertaken for Crohn’s disease. We do not know how much is 
spent on side effect management. Also we cannot define the disease costs per mild, 
moderate, and severe form of the disease.
Related to the lack of the national registry, we cannot quantify DASS and IBDQ 
improvements related to treatments applied; therefore we cannot define price per 
HRQOL improvement.
What we can do at this point is to improvise: to extrapolate epidemiological data 
[36, 37] and estimate the incidence and the prevalence of the disease in Croatia. 
Then we can apply international data to estimate patients’ split and treatment 
outcomes and average cost per patient group. Then we can use Markov models and 
analyses as implemented by Lindsay et al. [35].
The above mentioned leaves calculation table empty at basic input level. Our 
first conclusion is that there is an essential need to implement national IBD registry 
to summarize the data needed for an economic analysis model.
Our second conclusion taken from CD example is that if we want to better drive 
our HC resources, Cost-effectiveness analysis needs to become the key method for 
assessing costs and benefits of alternative ways of allocating resources to assist 
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decisions aiming to improve efficiency. An efficient allocation of resources implies 
that no further health gains can be achieved by allocating the same resources 
differently. The analysis is based on maximizing health effects subject to a cost 
constraint, where costs are measured in monetary units and health effects in 
non-monetary units, such as life years or quality-adjusted life years. QALYs are 
constructed by adjusting life years for the quality of life in which they are spent. 
To achieve this, the number of years in a health state is multiplied by utility weight 
between 0 (dead) and 1 (full health). To determine whether a treatment is cost-
effective compared to alternative, the cost per gained unit of effectiveness (i.e., 
cost per QALY gained) must be compared with the willingness to pay (WTP) for a 
gained unit of effectiveness (i.e., the value of QALY gained). WTP can be defined 
as the price the payer is willing to pay for a QALY. If the price per unit increase in 
effectiveness exceeds the target price, then the program is cost-effective. Without 
the information about the price per unit increase in effectiveness, CEA gives no 
information on whether an intervention is cost-effective. The value of a QALY dif-
fers between courtiers and is logically related to the level of GDP.
7. CD example/Markov models: how to implement it in Croatia
The model characterizes the disease severity by two discrete “on-treatment” 
health states: (1) remission (DAI </=150) and (2) response but no remission/active 
state (CDAI >150). All patients started in the active state and remained as such 
for the first model cycle. At the end of the first and each subsequent model cycle, 
patients either remained in the active state or moved to a different health state. In 
the illustration of the model bellow, two separate numbers denote different transi-
tions in standard care and infliximab* treatment arm. If single number, there were 
no differences between the arms.
Patients responding to treatment and achieving CDAI </= 150 moved to the 
remission and remained on treatment. Patients responding but not achieving remis-
sion remained in the active state and continued treatment [11]. Nonresponders or 
discontinuing-from-treatment patients moved to the nonresponding active state. 
Once patients failed the treatment and discontinued from the treatment, they could 
not go back to the on-treatment status, but they were followed up to capture costs 
and outcomes.
As obvious from diagrams, both on-treatment and off-treatment patients could 
transition to surgery. Following surgery, patients could either undergo repeat surgery 
due to immediate complications, therefore remaining in surgery state, or they could 
move to a post surgery health state (remission or post surgery complications). Patients 
in post surgery remission could continue in the same health state, enter surgery for 
repeated procedure, enter post surgery complication state, or have CD recurrence and 
move to a nonresponsive active state. Infliximab failures were not re-treated, and also 
patients with post surgery complications could continue in the same health state, enter 
surgery, respond to treatment for their complications and enter post surgery remis-
sion, or have recurrence of CD and enter nonresponding active state.
In model adjusted for fistulizing DC, on-treatment health states of remission 
were further sub classified as with or without failure. This gives four on-treatment 
health states as shown in the diagram. The rest of the model was identical to the 
active luminal CD model.
The patient and treatment parameters (sources of efficacy estimation, treatment 
regimen, comparators, treatment strategy) in Markov models are based on standard 
treatment protocols and ACCENT trial evidence [11, 18]. Treatment horizon was 
5 years.
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Before establishing national registry, as suggested in Lindsay trial [35], transi-
tion probabilities for different health states could be taken from published random-
ized placebo-controlled induction studies [38].
Consequently, before establishing the national registry, probability of surgery, 
postsurgical states, and CD recurrence are to be obtained from the literature [39–44].
Costs resulting from the impact of CD on QOL and productivity and overall 
burden to the Croatian society are difficult to estimate based on international 
trial findings [45, 46] and might be disregarded at this initial point of establishing 
CEA model.
Drug costs per indication are drug acquisition costs (price per pack), drug 
administration costs (price per infusion in the case of infliximab), and price of 
concomitant drugs (immunomodulators, aminosalisylates, corticosteroids).
These drug costs can be obtained from HZZO or from the national CD registry.
Alternatively we can calculate drug acquisition costs assuming an average body 
weight of 60 kg based on NICE guidance for infliximab case.
Surgery, hospitalization, and other assessment costs should be obtained from 
HZZO [47].
The primary efficacy measure of Croatian CD model should be QALY, gains 
being driven by quality-of-life benefits. Utility as a measure places a value on 
HRQOL, ranging from 1 (perfect health) to 0 (death). Quality-adjusted life years 
are then derived by multiplying the time in a health state by the appropriate 
utility score. Cost-utility analysis represents incremental cost per QALY gained. 
Logically, differences between treatments should be expressed as the differences 
in incremental costs per QALY. Cost and outcomes are to be calculated in accor-
dance with NICE guidelines, separately for the entire cohort of patients in treat-
ment arms, regardless of their response rates, and discounted to present values at 
3.5% per annum.
7.1 Markov model for active luminal CD
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7.2 Markov model modified for fistulizing CD
8. Conclusions
Based on international trials, TNF antagonists’ maintenance therapy may bring 
significant improvements in patients’ HRQOL in adult patients with severe active 
luminal or fistulizing CD.
Based on international cost-utility analyses, it can be concluded that a substan-
tial part of TNF antagonist acquisition costs could be offset by savings on other 
disease-related costs in patients not responding to or intolerant to steroids and 
immunomodulators.
It is essential to establish Croatian National Registry of Crohn’s disease to 
prospectively evaluate epidemiology, clinical subgroups, transition from states, 
treatment outcomes, and costs.
Markov models combined with registry data and findings from international tri-
als represent solid frame to calculate pharmacoeconomic impacts of Crohn’s disease 
treatments.
From the payers perspective, it seems to be a must to establish a QALY-based 
process of assessment of new therapeutic options and HC technologies in Croatia. 
Using this methodology, payers would develop comparable data even in different 
indications/treatment options, evaluate objectively contributions for incremental 
costs per QALY, and allocate HR resources accordingly.
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